For decades, potent combinations of surgery, radiation, and chemotherapy have treated glioblastoma, the most aggressive type of adult brain cancer. However, in most cases, the tumour returns. A new study from the United States explains why this disease frequently outsmarts treatment and suggests a whole different method for improving results.

Brown University Health researchers discovered that glioblastoma survives by exploiting variations among its own cells in a study published on November 10 in Cell Reports. Cancer cells behave differently inside a single tumour. Some are quickly destroyed by chemotherapy, whilst others are better able to repair damage and survive. These surviving cells eventually drive the cancer's recurrence.

Rather than developing yet another medicine to target cancer cells, the researchers focused on the basic mechanisms that cause this internal dysfunction. They discovered miR-181d, a small molecule that works as a key regulator of how glioblastoma cells respond to treatment. Researchers believe that by altering this chemical, they can reduce tumours' ability to resist therapy.

Glioblastoma is especially difficult to treat because its cellular diversity hinders chemotherapy from functioning consistently. When medications are used to treat tumours, only certain cells are destroyed, while others adapt and survive.

"Traditionally, researchers have focused on the overall behaviour of a tumour by studying the average response across all the individual cells," said Dr Clark Chen, senior author of the study and professor of neurosurgery at Brown University Health. "Our findings substantially changed that strategy. Rather than focusing on the average response, we looked at the variances between individual cells inside the same tumour, and what we discovered may transform how we treat glioblastoma."

The researchers discovered that miR-181d regulates how much of the DNA-repair protein MGMT each cancer cell generates. MGMT helps tumour cells survive chemotherapy by repairing DNA damage induced by cancer medicines. Cells that produce more MGMT are better able to heal, but those with lower levels are more likely to perish.

This uneven healing system keeps the glioblastoma alive. The researchers also discovered that chemotherapy reduces miR-181d levels, which unintentionally increases cell differences and allows more of them to withstand treatment.

In laboratory trials, reinstalling miR-181d within tumours decreased this variation. Cancer cells began to behave more uniformly, reducing their particular survival advantages. Once synchronised, the tumour as a whole became far more responsive to chemotherapy.

"This is an exciting step forward," said Dr Gatikrushna Singh, an assistant professor of neurosurgery at the University of Minnesota and the study's primary collaborator. "Scientifically, it explains why cancers have so much intrinsic heterogeneity. Clinically, it opens the door to gene-therapy techniques that could be truly transformative for many glioblastoma patients."

The findings have already prompted the creation of a potential novel therapeutic for stabilising miR-181d levels in glioblastoma tumours. While currently experimental and not yet available to patients in India or abroad, researchers believe the method could someday be used alongside regular chemotherapy to increase survival.

Experts point out that this is not a cure. However, it signals a paradigm shift in cancer research—from attempting to eradicate tumours cell by cell to managing how they function. For glioblastoma, a condition historically associated with treatment failure, the study provides a unique blend of clarity and cautious optimism.